TrialNaunyn-Schmiedeberg's archives of pharmacology2026

Evaluation of serum tumor markers in assessing the efficacy of TP (Paclitaxel plus Carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual target therapy in HER2-positive breast cancer.

Lei Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.